A New Approach to Preventing Side Effects of Lipid-Lowering Therapy Using Personalized Cytoprotection in Patients with Coronary Heart Disease
In order to develop a personalized approach to preventing side effects of statins, a clinical (in vivo) and experimental (in vitro) study of 60 patients with coronary heart disease was conducted. The comparison group (n = 30) received basic therapy (atorvastatin 20 mg/day). The main group (n = 30) additionally received the etoxidol cytoprotector. Atorvastatin monotherapy was found to cause a significant increase in markers of myopathy and myocardial cytolysis (total creatine phosphokinase CPK, MB-CPK, myoglobin) with a moderate hypolipidemic effect. In the etoxidol group, the levels of these markers decreased. The in vitro study showed that the cytoprotective activity of etoxidol was maximum in cases of hypercholesterolemia (CH > 6.6 mmol/l), and that of trimetazidine – in cases of normal/low CH (< 5.3 mmol/l). Personalized prescription of a cytoprotector depending on the level of total blood cholesterol is proposed as a new method for preventing the side effects of statin therapy.
Romashchenko O.V., Khokhlov A.L., Alferov P.K., Grishchenko N.D., Nadezhdin S.V., Yakunchenko T.I., Mevsha O.V., Rumbesht V.V., Kopylash A.I. 2025. A New Approach to Preventing Side Effects of Lipid-Lowering Therapy using Personalized Cytoprotection in Patients with Coronary Heart Disease. Challenges in Modern Medicine, 48(3): 305–319 (in Russian). DOI: 10.52575/2687-0940-2025-48-3-305-319. EDN: KBQHDH
While nobody left any comments to this publication.
You can be first.
Andryashkina D.Yu., Klimenko A.A., Karina I.O., Chernyaeva A.Yu., Doronina S.N. 2024. Recommendations for Lipid-Lowering Therapy 2023 – What's New? General Medicine. 1: 37–46 (in Russian). doi: 10.24412/2071-5315-2024-13085
Barbarash O.L., Karpov Yu.A., Panov A.V., Akchurin R.S., Alekyan B.G., Alekhin M.N., Aronov D.M., Harutyunyan G.K., Belenkov Yu.N., Boytsov S.A., Boldueva S.A., Boschenko A.A., Bubnova M.G., Bulkina O.S., Vasyuk Yu.A., Galyavich A.S., Glezer M.G., Golubev E.P., Golukhova E.Z., Grinstein Yu.I., Davidovich I.M., Yezhov M.V., Zavadovsky K.V., Irtyuga O.B., Karpov R.S., Kashtalap V.V., Koziolova N.A., Korennova O.Yu., Kosmacheva E.D., Koshelskaya O.A., Kukharchuk V.V., Lopatin Yu.M., Merkulov E.V., Mironov V.M., Martsevich S.Yu., Mirolyubova O.A., Mikhin V.P., Nedoshivin A.O., Nikulina N.N., Nikulina S.Yu., Oleinikov V.E., Panchenko E.P., Perepech N.B., Petrova M.M., Protasov K.V., Saidova M.A., Samko A.N., Sergienko I.V., Sinitsyn V.E., Skibitsky V.V., Soboleva G.N., Shalaev S.V., Shaposhnik I.I., Shevchenko A.O., Shiryaev A.A., Shlyakhto E.V., Chumakova G.A., Yakushin S.S. 2024. Clinical Practice Guidelines for Stable Coronary Artery Disease. Russian Journal of Cardiology. 2024; 29(9): 6110 (in Russian). doi: 10.15829/1560-4071-2024-6110
Vinogradov V.V. 1989. Hormones, Adaptation and Systemic Reactions of the Organism. Minsk: Science and Technology. – 223 p. (in Russian).
Volkova M.V., Ragino Y.I. 2021. Modern Biomarkers of Oxidative Stress Estimated by Immuno-Enzymal Analysis. Ateroscleroz. 17(4): 79–92 (in Russian). doi:10.52727/2078-256X-2021-17-4-79-92
Vorobiova E.N., Simonova G.I., Vorobiov R.I., Leschenko I.G. 2010. Free-Radical Oxidation and Atherosclerosis. Ateroscleroz. 6(2): 20–27 (in Russian).
Ezhov M.V., Sergienko I.V., Kukharchuk V.V. 2023. Clinical Guidelines for Lipid Disorders. 2023. What's New. Atherosclersis and Dyslipidemias. 3(52): 5–9 (in Russian). doi: 10.34687/2219–8202.JAD.2023.03.0002
Ezhov M.V., Chubykina U.V., Dmitriev V.A. 2023. Difficulties in Achieving Target Levels of Low-Density Lipoprotein Cholesterol in Patients with Atherosclerotic Cardiovascular Diseases in Real Clinical Practice. Atherosclerosis and Dyslipidemia. 4: 27–34 (in Russian). doi: 10.34687/2219-8202.JAD.2023.04.0003
Iskova I.A., Klyaritskaya I.L., Tsapyak T.A., Krivoy V.V., Maksimova E.V. 2021. Statin-Induced Myopathy. Crimean Therapeutic Journal. 3: 64–70 (in Russian).
Karpov Yu.A. 2023. A New Vector for Reducing Cardiovascular Risk – Intensive Lipid-Lowering Therapy. Atmosphere. Cardiology news. 1: 3–10 (in Russian). doi: 10.24412/2076-4189-2023-12836
Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Bubnova M.G., Balakhonova T.V., Gurevich V.S., Kachkovsky M.A., Konovalov G.A., Konstantinov V.O., Malyshev P.P., Pokrovsky S.N., Sokolov A.A., Sumarokov A.B., Gornyakova N.B., Obrezan A.G., Shaposhnik I.I. 2020. Diagnostics and Correction of Lipid Metabolism Disorders for the Prevention and Treatment of Atherosclerosis. Russian Guidelines, VII Revision. Atherosclerosis and dyslipidemia. 1: 7–40 (in Russian). doi: 10.34687/2219-8202.JAD.2020.01.0002
Larionov P.M., Malov A.N., Mandrik M.M., Maslov N.A., Orishich A.M. 2003. Changes in the Spectrum of Laser-Induced Fluorescence of Myocardial Tissue as its Viability Decreases. Journal of Applied Spectroscopy. 70(1): 38–42 (in Russian). doi: 10.1023 / A: 1023212206592
Leonova M.V. 2022. Effects of nocebo and drusebo in Determining Statin-Induced Muscle Symptoms. Meditsinskiy Sovet. 16(17): 136–142 (in Russian). doi:10.21518/2079-701X-2022-16-17-136-142
Mitroshina E.V., Mishchenko T.A., Vedunova M.V. 2015. Determination of the Viability of Cell Cultures. Study Guide. Nizhny Novgorod: 21p. (in Russian).
Pateyuk I.V. 2024. Statins in the Treatment of Patients with Dyslipidemia: General Principles and Algorithm for Choosing a Drug. Recipe. 27(2): 166–179 (in Russian). doi:10.34883/PI.2024.27.2.003
Pokrovsky M.V., Romashchenko O.V., Nadezhdin S.V., Morozova A.V., Savvina Yu.A. 2020. Method for Determining the Cytoprotective Properties of a Medicinal Product. Know-How Certificate No. 336 Dated November 9, 2020. Belgorod, National Research University "BelGU" (in Russian).
Romashchenko O.V. 2021. Personalized Approaches to the Administration of Trimetazidine as a Cytoprotector in Patients with Coronary Heart Disease. Russian Journal of Cardiology. 6: 106–114 (in Russian). doi: 10.15829/1560-4071-2021-4532
Romashchenko O.V., Khokhlov A.L., Alferov P.K., Yakunchenko T.I., Pyatakovich F.A., Mevsha O.V. 2024. Effect of the Combination of Atorvastatin and Ethylmethylhydroxypyridine Malate on the Lipid Profile in Patients with Coronary Heart Disease. Actual Problems of Medicine, 47(4): 449–464 (in Russian). doi: 10.52575/2687-0940-2024-47-4-449-464
Ryabikhin E.A. 2023. Rational Therapy of Patients with Ischemic Heart Disease, what will the Addition of Trimetazidine Give us? Are We Using All the Possibilities in the Treatment of Patients with Ischemic Heart Disease? Atmosphere. Cardiology News. 2: 46–51 (in Russian). doi: 10.24412/2076-4189-2023-12867
Sergienko I.V. 2023. Russian Clinical Guidelines for Lipid Metabolism Disorders. 2024. What's New? RMJ. 4: 12–16 (in Russian).
Soboleva N.I. 2020. Undesirable Side Effects of Statins in the Treatment of Elderly Patients. Clinical Gerontology. 26(5–6): 34–38 (in Russian). doi: 10.26347/1607-2499202005-06034-038
Susekov AV. 2024. Statins in the Practice of an Internal Medicine Specialist: A Review. Consilium Medicum. 26(10): 641–648 (in Russian). doi: 10.26442/20751753.2024.10.202995
Khapokhov I.M., Ryazanov A.S., Melnikova L.V., Makarovskaya M.V. 2025. Personalized Approach to the Management of Patients with Cardiovascular Diseases in Outpatient Practice (Literature Review). News of Higher Educational Institutions. Volga Region. Medical Sciences. 1(73): 99–114 (in Russian). doi: 10.21685/2072-3032-2025-1-8
Khokhlov A.L., Romashchenko O.V., Rumbesht V.V., Alferov P.K., Grishchenko N.D., Gorbach T.V., Kukes V.G. 2023. The General Concept of a Patient-Oriented Approach to the Use of Drugs with Cytoprotective Activity in Patients with Coronary Heart Disease. Patient-Oriented Medicine and Pharmacy. 1(3): 1–14 (in Russian). doi: 10.37489/2949-1924-0019
Chaulin A.M. 2022. The Main Side Effects of Statins in Clinical Practice. Clinical Practice. 13(2): 98–107 (in Russian). doi: 10.17816/clinpract108076
Chaulin A.M., Duplyakov D.V. 2023. Statins and Highly Sensitive Cardiac Troponins: Cardiotoxicity or Cross-Reactivity? Rational Pharmacotherapy in Cardiology. 19(2): 209–216 (in Russian). doi: 10.20996/1819-6446-2023-04-01
Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S. 2019. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73(24): 3168–3209. doi: 10.1016/j.jacc.2018.11.002
Khokhlov A.L., Romaschenko O.V., Rumbesht V.V., Yakunchenko T.I., Zhernakova N.I., Zakirova L.R., Kukes V.G. 2024. Leukocyte as an Adequate Model for Studying Changes in Energy Metabolism in Heart Cells under the Influence of Cardiocytoprotectors in Myocardial Ischemia. Acta biomedica scientifica. 9(5): 114–121. doi:10.29413/ ABS.2024-9.5.12
Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. 2020. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur. Heart. J. 41(1): 111–188. doi: 10.1093/eurheartj/ehz455
Masana L., Plana N., Andreychuk N., Ibarretxe D. 2023. Lipid Lowering Combination Therapy: From Prevention to Atherosclerosis Plaque Treatment. Pharmacological Research. 190: 106738. doi: 10.1016/j.phrs.2023.106738
Punetha M., Saini S., Chaudhary S., Bala R., Sharma M., Kumar P., Kumar D., Yadav P.S. 2023. Mitochondria-Targeted Antioxidant MitoQ Ameliorates ROS Production and Improves Cell Viability in Cryopreserved Buffalo Fibroblasts. Tissue Cell. 82: 102067. doi: 10.1016/j.tice.2023.102067
Ray K.K., Reeskamp L.F., Laufset U. 2022. Combination Lipid-Lowering Therapy as First-Line Strategy in Very High-Risk Patients. European Heart Journal. 43(8): 830–833. doi:10.1093/eurheartj/ehab718
Shivakumar A., Yogendra Kumar M.S. 2018. Critical Review on the Analytical Mechanistic Steps in the Evaluation of Antioxidant Activity. Crit. Rev. Anal. Chem. 48(3): 214–236. doi: 10.1080/10408347.2017.1400423
Yurkovich J.T, Hood L. 2019. Blood Is a Window into Health and Disease. Clinical Chemistry. 65(10): 1204–1206, doi:10.1373/clinchem.2018.299065
Wei J., Gao D.F., Wang H., Yan R., Liu Z.Q., Yuan Z.Y., Liu J., Chen M.X. 2014. Impairment of Myocardial Mitochondria in Viral Myocardial Disease and its Reflective Window in Peripheral Cells. PLoS One. 9(12): e116239. doi: 10.1371/journal.pone.0116239
The work was carried out with the financial support of Medimex LLC (Kurgan, Russia).